Among several beneficial cardiovascular actions of statins, experimental studies have suggested that statins may also induce a mild blood pressure (BP) reduction. However, clinical data were controversial and the potential hypotensive statin effect remains uncertain. This study aimed to investigate the effect of atorvastatin on ambulatory BP in patients with mild hypertension and hypercholesterolaemia. A total of 50 patients with mild hypertension and hypercholesterolaemia participated in this double-blind, randomized, placebo-controlled study. Patients were randomized to either 10 mg atorvastatin or placebo for 26 weeks. Background antihypertensive treatment, if any, remained unchanged during follow-up. At baseline and study-end (26 weeks), ambulatory BP monitoring and blood sampling for determination of standard biochemical and safety parameters were performed in all participants. BP loads were defined as the percentage of BP measurements exceeding the hypertension threshold of 140/90 mm Hg for daytime and 125/75 mm Hg nighttime period. Atorvastatin significantly reduced 24-h systolic and diastolic BP (DBP; median (range)) as compared with placebo (À5.0 (À21.0, 4.0) vs þ 1.0 (À6.0, 7.0) mm Hg, Po0.001 and À3.0 (À16.0, 2.0) vs þ 0.1 (À7, 4) mm Hg, Po0.01, respectively). Reductions in systolic and DBP loads during follow-up were also evident in the atorvastatin, but not in the placebo group. BP-lowering effects of atorvastatin were consistent in both daytime and nighttime periods. This study shows a mild, but consistent throughout the 24-h period BPlowering effect of atorvastatin in patients with mild hypertension and hypercholesterolaemia. This beneficial effect of atorvastatin on BP may represent another pathway through which this drug class provides cardiovascular risk reduction.
Introduction
HMG-CoA reductase inhibitors (statins) are extensively used in daily clinical practice as the first-line treatment for elevated low-density lipoprotein (LDL) cholesterol levels. 1 Large-scale randomized clinical trials evaluating the effects of statins on hard cardiovascular outcomes have demonstrated that their lipid-lowering effects are translated into clinical benefit in both primary 2 and secondary prevention of cardiovascular events. 3 Accumulated evidence during the past years suggests that the cardiovascular benefits of statins may extend above and beyond lipid lowering. The beneficial actions of statins on vasculature include reduction of vascular inflammation, improvement of insulin sensitivity and endothelial function, inhibition of vascular smooth muscle cells migration and proliferation, reduction of oxidant stress, and inhibition of platelet adhesion. 4, 5 In this context, it has been suggested that statin treatment may be also associated with a mild hypotensive effect. Blood pressure (BP) reductions with statin treatment were originally revealed in different animal models of hypertension. 6, 7 These potential BP-lowering properties are further supported by background data, which have uncovered a number of statin actions that could contribute to BP amelioration. 5, 8, 9 Despite the rather solid mechanistic background, the findings of human studies evaluating the statin effects on BP seem rather conflicting. Early clinical studies in this field suffered from important methodological limitations (uncontrolled and non-randomized designs, small sample sizes, and short duration of follow-up). [10] [11] [12] In addition, most of these studies were based on office BP recordings, although ambulatory BP monitoring (ABPM) has been reported to have several advantages over conventional office BP measurements in detection of small changes in BP levels. 13 A recent metaanalysis of these studies also failed to provide a definite answer to the question under study, as its findings are unavoidably affected by the limitations of the individual studies included in the pooled analysis.
14 Uncertainty around the potential BPlowering properties of statins remains even after the publication of recent large-scale randomized clinical studies; 15, 16 these studies also gave contradictory results, while the net statin effect on BP in some of them 16 was potentially influenced by concurrently administered antihypertensive medication.
This study aimed to objectively investigate the potential effects of 6-month low-dose atorvastatin treatment on ambulatory BP in patients with mild hypertension and a recent diagnosis of hypercholesterolaemia.
Materials and methods

Study population
A total of 50 patients with mild hypertension and hypercholesterolaemia were enrolled in this single-center, double-blind, randomized, parallelgroup, placebo-controlled study. The study protocol was approved by the Ethics Committee of Medical School of Aristotle University of Thessaloniki as well as by the National Regulatory Drug Agency of Greece. This study was registered in ClinicalTrials. gov database (Identifier Number: NCT01126684). All protocol procedures were conducted in accordance with the Declaration of Helsinki (2002 Amendment) and all subjects provided informed written consent before study enrolment.
All study participants were originally evaluated at the Outpatient Hypertension Clinic of our department. Screening evaluation included a full medical history, physical examination and standard laboratory tests. Patients were eligible in this study if they had: (a) known mild hypertension with inadequate control under antihypertensive treatment and BP levels below 160/100 mm Hg or stage I hypertension of recent onset, defined according to international guidelines; 17 After completing all these tests, study subjects were randomized to receive double-blind treatment with either atorvastatin 10 mg once daily (n ¼ 25) or placebo (n ¼ 25) for 26 weeks (6 months). Randomization was carried out with computer-generated random numbers to allocate treatment in consecutive patients who fulfilled the inclusion/exclusion criteria and volunteered to participate in the study. Background antihypertensive treatment, if any, remained unchanged throughout the whole study period. All study participants were given standard recommendations for lifestyle changes according to current international guidelines 17 at their regular outpatient visits before the study, including the screening visit; at baseline, they were advised to keep their physical activity and dietary habits unchanged during the follow-up. Study participants visited the Outpatient Hypertension Clinic of our department every 2 months for BP measurement, physical exam and standard laboratory tests. Adherence of participants to the study regimen was assessed by study investigators in the scheduled follow-up visits using standardized procedures (pill count). At 26 weeks (6 months), subjects visited again the Clinical Research Laboratory of our department where all baseline measurements were repeated.
Measurements Ambulatory BP monitoring. Ambulatory BP was monitored using a Spacelabs 90207 device (Spacelabs Medical, Redmond, WA, USA) at baseline and the end of the study. 18 The ABPM was assessed for 25 h. The data of the first hour were not included in the analysis, and this period was used to enable patients to become comfortable with the equipment. The monitor recorded ambulatory BP three times an hour between 08.00 and 24.00, and hourly between 24.00 and 08.00 h. Readings were used for the analysis only if 480% of measurements were valid with no more than two non-consecutive day hours (08.00-24.00 o'clock) with fewer than two valid readings, and no more than one night hour (24.00-08.00 o'clock) without reading. In case of invalid ambulatory BP measurement, study participants were invited to repeat the ABPM in the next day. Invalid ambulatory BP measurements were obtained in 4 out of 50 patients at baseline evaluations; all patients repeated and achieved a successful ABPM at the next day. The hypertension thresholds used were 140/90 mm Hg for daytime and 125/75 mm Hg for nighttime. 13 Mean systolic BP (SBP), diastolic BP (DBP), mean BP (MBP), systolic and DBP loads were calculated. Systolic and DBP loads were defined as the percentage of BP measurements exceeding the hypertension threshold of 140/ 90 mm Hg for daytime period and 125/90 nighttime period. 13, 19 Nocturnal BP dip (%) was calculated as 100 Â (1 ¼ nighttime/daytime BP ratio). Patients with a nocturnal BP dip o10% were classified as non-dippers, and patients with nocturnal BP dip X10% were classified as dippers. 13 Biochemical analyses. Plasma glucose, total cholesterol, HDL-cholesterol and LDL-cholesterol, triglycerides, serum electrolytes and other routine biochemical parameters were measured with Roche/ Hitachi 912 automatic analyzer (Roche Diagnostics, Basel, Switzerland) using standard laboratory methods. Haematological measurements were made with a Coulter MicroDiff II automated counter (Coulter Corporation, Miami, FL, USA). Total plasma apolipoprotein A-I, apolipoprotein B, and lipoprotein A were determined by immunonephelometry, using the Behring Nefelometer 100 (Dade Behring Inc, Deerfield, IL, USA)
Statistical analysis
Sample size calculation was carried out with nQuery advisor version 5.0. software (Statistical Solutions, Boston, MA, USA). The study had above 80% power to detect a difference of 4.0 mm Hg in change of mean 24-h SBP, which was the primary study end point during follow-up between atorvastatin and placebo groups, with a ¼ 0.05 and assuming a standard deviation (s.d.) of 8 mm Hg.
Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS) version 17.0 for windows XP (SPSS Inc, Chicago, IL, USA). Continuous variables were expressed as mean±s.d. Baseline differences between the two study groups were evaluated with paired t-tests or w 2 -square tests. For comparisons between the baseline and the end of the study in each study group, paired t-tests or Wilcoxon's Signed Rank tests were used according to the normality of the distribution. Between-group differences were compared using unpaired t-tests or Mann-Whitney U-tests where appropriate. To identify possible relationships between the changes in the parameters under study, bivariate correlation coefficients (r) were calculated using the Pearson's product formula. A P-value level o0.05 (two-tailed) was considered statistically significant.
Results
Demographic and biochemical characteristics, as well as mean 24-h SBP and DBP levels at baseline for the atorvastatin and placebo groups are presented in Table 1 . No significant differences in body weight, body mass index, waist-to-hip ratio, serum lipids and other standard biochemical parameters were observed between groups at baseline evaluation. Similarly, baseline mean 24-h SBP and DBP levels were not different between study groups at baseline. As shown in Figure 1 , small but significant reductions in mean 24-h SBP, and DBP between baseline and study-end were observed in the atorvastatin group (146. Table 2 ). These BP-lowering effects of atorvastatin were consistent in both daytime and nighttime periods. Overall, 24-h changes between baseline and 26 weeks in the atorvastatin and placebo groups (median (range)) were (À5.0 (À21.0, 4.0) vs þ 1.0 (À6.0, 7.0) mm Hg, Po0.001) for SBP and (À3.0 (À16.0, 2.0) vs þ 0.1 (À7, 4) mm Hg, Po0.01) for DBP ( Table 2) . With regard to dipping status, no significant differences in the percentage of dippers were evident between the atorvastatin and placebo groups at baseline and study-end (76 vs 68%, P ¼ 0.529 for SBP dip and 80 vs 84%, P ¼ 0.713 for DBP dip at baseline, and 60 vs 68%, P ¼ 0.556 for SBP dip and 84 vs 64%, P ¼ 0.107 for DBP dip at study-end).
Body weight, body mass index and waist-to-hip ratio remained unchanged during the 26-week observational period in both atorvastatin and placebo groups (Table 3) . With regard to serum lipids, atorvastatin treatment was associated with significant reductions in total cholesterol, LDL-cholesterol and triglyceride levels after 26 weeks of treatment as compared with placebo (Table 3 ). In addition, atorvastatin significantly reduced total plasma lipoprotein A and apolipoprotein B levels vs baseline, and was associated with a trend towards increase in apolipoprotein A-I levels. In contrast, lipoprotein A, apolipoprotein A-I and apolipoprotein B levels were not significantly changed between baseline and study-end in the placebo group. Changes during follow-up in mean 24-h SBP or DBP levels in the atorvastatin group were not significantly correlated with changes in total cholesterol or LDL-cholesterol levels (data not shown).
The effects of atorvastatin treatment on standard safety parameters are depicted in Table 4 . Haematocrit and haemoglobin levels, renal function and liver function tests remained unaffected during the follow-up in both active treatment and placebo groups.
Discussion
The present double-blind, randomized, placebocontrolled clinical study aimed to evaluate the potential effects of low-dose atorvastatin treatment on ambulatory BP in patients with mild hypertension and hypercholesterolaemia. The study's main finding was that the treatment with 10 mg atorvastatin for 26 weeks produced mild but clinically meaningful reductions in mean 24-h SBP, DBP and MBP levels, as well as in systolic and DBP loads compared with placebo. Of note, the BP-lowering effects of atorvastatin in our study were consistent in both daytime and nighttime periods.
Several previous clinical studies investigated the effects of statins on BP. [10] [11] [12] [20] [21] [22] Some studies showed statin treatment to be associated with significant reductions in BP levels, 20, 21 whereas others failed to confirm this finding. 11, 12 However, the absence of significant BP reduction in the latter studies could be attributed to methodological issues, rather than absence of true treatment effect. In particular, in several studies showing no or insignificant changes in BP levels, BP was not the primary end point. 10, 23 Further, most statin studies failing to show significant BP lowering were also limited by small sample sizes and short duration of follow-up, while BP measurement was based on conventional office readings. [10] [11] [12] In contrast, studies using ABPM, although fewer in number and still having limitations (short duration of follow-up, small sample sizes), showed significant reductions of about 5/3 mm Hg in 24-h SBP/DBP in hypertensive patients. 22, [24] [25] [26] Only one recent study with ABPM reported non-significant differences between a statin and placebo; however, that should be rather attributed to the low number of subjects (n ¼ 13) and the short total duration (6 weeks). 27 A meta-analysis of 20 randomized studies of statin therapy, in which background antihypertensive treatment remained unchanged also slightly supported a beneficial effect, showing a significant reduction of 1.9 mm Hg in SBP vs placebo or control hypolipidemic therapy. 14 The findings of our study are in line with that of the University of California/San Diego statin trial, 15 where 973 patients without cardiovascular disease were randomized to simvastatin 20 mg, pravastatin 40 mg daily or placebo for 6 months, and office BP was reduced by 2.2/2.4 mm Hg more in statin groups. 15 Hypertension was not an inclusion criterion in this study, but statins also showed significant BP reductions in normotensive participants. 15 Statin effects on BP were also evaluated in the Plaque Hypertension Lipid-Lowering Italian Study (PHYL-LIS) study, 16 which randomized 508 patients with mild hypertension, and hypercholesterolaemia were randomized to hydrochlorothiazide 25 mg or fosinopril 20 mg with or without the addition of pravastatin 40 mg daily in a 2 Â 2 factorial design. Both antihypertensive agents effectively lowered BP after 2.6 years of treatment, but addition of pravastatin did not cause any further reductions in office and ambulatory BP. 16 A difference between PHYL-LIS and the present study, showing BP lowering with atorvastatin, is that patients in PHYLLIS received concurrent treatment with pravastatin and effective antihypertensive agents; therefore, any mild BP-lowering effect of pravastatin in PHYLLIS trial could be potentially obscured by the confounding effect of the concurrently administered antihypertensives. In our study antihypertensive agents were given as background treatment remaining unchanged throughout the study, in an attempt to investigate the net effect of atorvastatin on ambulatory BP.
The BP-lowering properties of statins are supported by background data suggesting potential mechanisms through which they may influence BP. Statins could improve endothelial function and promote vasodilatation through various actions, such as increased endothelial nitric oxide synthase expression, 28 interference with the vasoconstricting action of endothelin-1, 20 and reduction in intracellular Ca 2 þ concentration in vascular smooth muscle cells. 29 Human studies showed that statins reduce aortic pulse wave velocity in patients with hypertension, 10 suggesting improvement of elastic properties of large arteries as another potential BPlowering mechanism. 5 Further, in vitro studies reported that statins downregulate the expression of angiotensin II type I receptor in vascular smooth muscle cells; 6 thus, interference with the reninangiotensin system could also participate in a hypotensive action. Important strengths of this study include the double-blind, randomized, placebo-controlled design; the use of ABPM, being the gold standard technique for BP measurement and providing information for BP changes throughout the 24-h period;
17 a carefully calculated sample size (providing 480% power to detect a between-group difference of 4 mm Hg in ambulatory SBP at study-end); and the fact that background treatment was held carefully with constant follow-up. However, there are still some potential limitations that have to be acknowledged. Duration of follow-up in our study was restricted to 26 weeks. Further, low-dose atorvastatin was studied in patients with mildly elevated BP, as we believed such patients are those to benefit the most from an additional BP-lowering effect of a statin and we aimed to keep our study population homogeneous. Whether these BP-lowering effects of low-dose atorvastatin are seen in normotensive individuals or patients with severe hypertension remains to be examined.
In conclusion, the present study shows that lowdose atorvastatin treatment of patients with mild hypertension and hypercholesterolaemia is associated with mild BP reductions, which are consistent throughout the 24-h period. This beneficial effect of atorvastatin on BP may represent another pathway through which statins provide cardiovascular protection and partly explain the major reductions in cardiovascular risk previously observed with these agents. 2, 3 Further, although not impressively large, these BP reductions must be considered clinically important in the context of the multidisciplinary approach of the patient with elevated cardiovascular risk, that is, with hypertension and dyslipidemia, and future guidelines should perhaps incorporate relevant data for the benefit of our patients. Finally, based on such findings, future clinical trials investigating the effect of antihypertensive agents on BP should also take into consideration (and possibly allocate or adjust for) any background statin treatment of their population in order to obtain unbiased results. What is known about this topic K Animal studies have shown that statins can lower blood pressure levels in experimental models of hypertension, through their pleiotropic effects on vasculature. K Clinical studies evaluating the potential blood pressurelowering properties of statins gave contradictory results; in some of these studies, statin treatment was associated with significant reductions in blood pressure levels, whereas other studies did not confirm a significant hypotensive action of these agents.
What this study adds K This double-blind, randomized, placebo-controlled study shows that low dose atorvastatin treatment for 6 months produces a mild, but statistically significant and perhaps clinically meaningful reduction of 5/3 mm Hg in 24-h systolic and diastolic blood pressure levels in patients with mild hypertension and hypercholesterolaemia. K The blood-pressure-lowering effects of atorvastatin in the present study were consistent throughout the 24-h period.
